Patrick Sanders

Patrick Sanders

Expertise: Tech stocks, Bank stocks, Buy-and-hold investing

Expertise:

Tech stocks
Bank stocks
Buy-and-hold investing

Education:

Graduate of Marshall University

About Patrick:

Patrick Sanders is a freelance writer, editor and stock market expert. He is founding editor of Invested, a daily stock market newsletter published by U.S. News & World Report, and he managed U.S. News’ investing advice section from 2015 to 2019.

He previously was deputy managing editor of InvestorPlace.com. He operated news websites in southeast Europe and Turkey, was the founding managing editor of the New York Times Editing Center and was Connecticut news editor for The Associated Press.

Patrick has made numerous media appearances as a stock market analyst and appeared on panels to discuss personal finance and investing. He served on the board of governors of the Society for Advancing Business Editing and Writing, and was co-chairman of the training committee to promote and develop training opportunities for business journalists throughout North America.

Patrick is a graduate of Marshall University and now resides in Maryland. Follow him on Twitter or connect on LinkedIn.

Recent Articles

A Fully Engaged Jack Dorsey Has Block Poised for More

Jack Dorsey is working just starting to work his magic. Block's plan to make bitcoin mining more accessible will be a big winner for SQ stock.

2022 Could Be a Whole New Ballgame for SoFi Technologies

SoFi Technologies finally secured a national bank charter and not a moment too soon for investors in beleaguered SOFI stock.

Vinco Ventures Is Just Grasping at Straws

Today, betting on Vinco Ventures means embracing it as a cryptocurrency play. What that means for BBIG stock remains to be seen.

This Could Become the Reset That Pinterest Stock Badly Needs

PINS stock is edging closer to its IPO price as the stock continues to tumble from its pandemic-inflated highs. Pinterest needs a reset.

Novavax Could Be the Biggest Bargain in the Market Right Now

If Novavax gets finally its Emergency Use Authorization next month from the FDA, then you can expect NVAX stock to skyrocket.